Hepatitis C drug may reduce antibiotic resistance, researchers say
A hepatitis C drug, telaprevir, can block the function of essential proteins in bacteria, which may allow to it be repurposed to limit antibiotic resistance, a study released Tuesday showed. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 23, 2021 Category: Consumer Health News Source Type: news
SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing Mpro inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 Mpro activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of Mpro in complex with MI-23, one of the most potent compounds, revealed its in...
Source: ScienceNOW - March 25, 2021 Category: Science Authors: Qiao, J., Li, Y.-S., Zeng, R., Liu, F.-L., Luo, R.-H., Huang, C., Wang, Y.-F., Zhang, J., Quan, B., Shen, C., Mao, X., Liu, X., Sun, W., Yang, W., Ni, X., Wang, K., Xu, L., Duan, Z.-L., Zou, Q.-C., Zhang, H.-L., Qu, W., Long, Y.-H.-P., Li, M.-H., Yang, R. Tags: Microbiology, Virology reports Source Type: news
Neutrons reveal unpredicted binding between SARS-CoV-2, hepatitis C antiviral drug
(DOE/Oak Ridge National Laboratory) Researchers at the Oak Ridge National Laboratory used neutron scattering to investigate the interactions between telaprevir, a drug used to treat hepatitis C viral infection, and the SARS-CoV-2 main protease, the enzyme responsible for enabling the virus to reproduce. Unforeseen changes in the electric charges were discovered in the drug binding site of the protease enzyme that were not predicted by prevailing computer simulations. The research provides key insights for advancing drug design and drug repurposing efforts to treat COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2021 Category: International Medicine & Public Health Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Severas reacciones cut áneas después de tratamiento combinado con los medicamentos Incivek (telaprevir), peginterferón alfa y ribavirina para la hepatitis C
El 19 de diciembre del 2012, La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) recibió informes sobre severas reacciones de la piel, algunas de ellas fatales, en pacientes que toman el medicamento Incivek (telaprevir) para la hepatitis C en combinación con los fármacos peginterferón alfa y ri bavirina (tratamiento combinado con Incivek). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Telaprevir more cost effective than boceprevir in triple therapy
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 31, 2019 Category: Drugs & Pharmacology Source Type: news
telaprevir (Incivek)
Title: telaprevir (Incivek)Category: MedicationsCreated: 7/21/2014 12:00:00 AMLast Editorial Review: 8/9/2017 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - August 9, 2017 Category: Nutrition Source Type: news
Incivek (Telaprevir Film-Coated Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news
Five things you need to know today, and why old folks should love Boston
Good morning, Boston! Here are the five most important things you need to know to help start your busy business day.
Why Vertex fell short on its job-creation vows to the city
In May 2011, just days after the FDA approval of the first-ever drug by Vertex Pharmaceuticals, company executives had a lot of reasons to be optimistic. The company’s hepatitis C treatment, Incivek, was more effective and easier to use than rival drugs, and 1,750 jobs at its new headquarters seemed eminently reachable.
When… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 12, 2015 Category: Biotechnology Authors: Doug Banks Source Type: news
Telaprevir Linked to Temporary Drop in Kidney FunctionTelaprevir Linked to Temporary Drop in Kidney Function
Using the protease inhibitor telaprevir may cause a temporary drop in kidney function in patients co-infected with HIV and hepatitis C virus (HCV), according to a small study. Reuters Health Information (Source: Medscape Nephrology Headlines)
Source: Medscape Nephrology Headlines - March 31, 2015 Category: Urology & Nephrology Tags: HIV/AIDS News Source Type: news
Can Current Investment in New Drugs Be Sustained?
When blockbuster drugs hit the market, they make big news and big profits. But for every blockbuster drug launched, there are an awful lot of disappointments.A good example is Vertex’s launch of the Hepatitis C drug Incivek. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 18, 2015 Category: Pharmaceuticals Source Type: news
Incivek / Telaprevir - Treatment for Chronic Hepatitis C
Incivek (telaprevir) is a protease inhibitor used for treating hepatitis C infections in liver patients. (Source: Drug Development Technology)
Source: Drug Development Technology - January 2, 2015 Category: Pharmaceuticals Source Type: news
Addition of telaprevir good value in genotype 1 hepatitis C
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2015 Category: Drugs & Pharmacology Source Type: news
Simeprevir Effective for Treating Chronic HCV Genotype 1 InfectionSimeprevir Effective for Treating Chronic HCV Genotype 1 Infection
Simeprevir plus peginterferon and ribavirin is noninferior to telaprevir plus peginterferon and ribavirin for treating previous null or partial responders with chronic hepatitis C virus (HCV) genotype 1 infection, according to Janssen's ATTAIN trial. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - December 16, 2014 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
Simeprevir-based therapy offers cost-effective alternative in treatment of hepatitis C
(University of Pennsylvania School of Medicine) Researchers at Penn Medicine, in collaboration with an international team, have shown that a protease inhibitor, simeprevir, along with interferon and ribavirin is as effective in treating chronic Hepatitis C virus infection as telaprevir with interferon and ribavirin, the standard of care in developing countries. Further, simeprevir proved to be simpler for patients and had fewer adverse events. The complete study is online and is scheduled to publish in January 2015 in The Lancet Infectious Diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2014 Category: Global & Universal Source Type: news
Vertex to End Sales of Hepatitis C Drug Telaprevir (Incivek)Vertex to End Sales of Hepatitis C Drug Telaprevir (Incivek)
Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its hepatitis C drug telaprevir (Incivek), whose use has been largely supplanted by new-comer sofosbuvir (Sovaldi) from Gilead Sciences. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - August 14, 2014 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news
